Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Ikuo MORI"'
Autor:
Yasunori Kogure, Hiroshi Handa, Yuta Ito, Masaki Ri, Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Masahiro Abe, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Toshiaki Hayashi, Kiwamu Akagi, Tomohiro Shinozaki, Takahiro Yoshida, Ikuo Mori, Shinsuke Iida, Takahiro Maeda, Keisuke Kataoka
Publikováno v:
HemaSphere, Vol 7, p e2665764 (2023)
Externí odkaz:
https://doaj.org/article/11421b9993d24536a7fba78bfcb51424
Autor:
Hiroya Taniguchi, Yuji Baba, Yoji Sagiya, Masamitsu Gotou, Kazuhide Nakamura, Hiroshi Sawada, Kazunori Yamanaka, Yukiko Sakakibara, Ikuo Mori, Yukiko Hikichi, Junpei Soeda, Hideo Baba
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 7, Pp 668-677 (2018)
Recent studies in RAS wild-type (WT) metastatic colorectal cancer (mCRC) suggest that the survival benefits of therapy using anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) antibodies combined
Externí odkaz:
https://doaj.org/article/10a652df2cb74644a94811edf9be7359
Autor:
Ikuo Mori
Publikováno v:
Material Cycles and Waste Management Research. 31:125-131
Autor:
Makoto Sasaki, Kenshi Suzuki, Yu Abe, Shigeki Ito, Kaichi Nishiwaki, Hiroshi Handa, Takaaki Chou, Junpei Soeda, Ikuo Mori, Tomohiro Shinozaki, Naoki Takezako
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S187-S188
Autor:
Masaki Iino, Yuichi Horigome, Yoriko Harazaki, Takahiro Kobayashi, Hiroshi Handa, Yasushi Hiramatsu, Taiga Kuroi, Kazuki Tanimoto, Kosei Matsue, Takahiro Yoshida, Ikuo Mori, Masahiro Abe, Kiwamu Akagi, Toshiaki Hayashi, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Takahiro Maeda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Tomohiro Shinozaki, Shinsuke Iida
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S172
Autor:
Yasuhiro Magata, Ikuo Mori, Taku Sugita, Yusuke Kondo, Takashi Horiguchi, Seigo Ishino, Mikako Ogawa
Publikováno v:
Nuclear Medicine Communications
Objectives The purpose of this study is the development of novel fluorine-18-fluorodeoxyglucose (18F-FDG)-PET and 99mTc-hexamethylpropylene amine oxime (HMPAO) SPECT methods with free-moving apparatus on conscious rats to investigate brain activity w
Autor:
Masamitsu Gotou, Hideo Baba, Yuji Baba, Yoji Sagiya, Junpei Soeda, Hiroshi Sawada, Yukiko Hikichi, Hiroya Taniguchi, Kazuhide Nakamura, Ikuo Mori, Kazunori Yamanaka, Yukiko Sakakibara
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 7, Pp 668-677 (2018)
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 7, Pp 668-677 (2018)
Recent studies in RAS wild-type (WT) metastatic colorectal cancer (mCRC) suggest that the survival benefits of therapy using anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) antibodies combined
Autor:
Mika Okai, Masaki Hosoya, Takashi Horiguchi, Hidenori Kamiguchi, Kazue Tsuchimori, Yusuke Kondo, Taku Sugita, Masanori Watanabe, Seigo Ishino, Ikuo Mori
Publikováno v:
Annals of Nuclear Medicine. 31:413-423
OBJECTIVE: \nOne of the major causes of diabetes and obesity is abnormality in glucose metabolism and glucose uptake in the muscle and adipose tissue based on an insufficient action of insulin. Therefore, many of the drug discovery programs are based
Autor:
Atsushi Ochiai, Junpei Soeda, Kohei Shitara, Hiroyuki Uetake, Kiwamu Akagi, Katsuya Tsuchihara, Takeharu Yamanaka, Takeshi Naitoh, Kentaro Yamazaki, Masamitsu Hihara, Eiji Oki, Yoshito Komatsu, Jun Watanabe, Ikuo Mori, Takayuki Yoshino, Kazunori Yamanaka, Kei Muro, Takeo Sato, Takeshi Kato
Publikováno v:
Journal of Clinical Oncology. 39:85-85
85 Background: The optimal choice of monoclonal antibodies (mAbs) for first-line treatment in patients (pts) with RAS ( KRAS/NRAS) wild-type metastatic colorectal cancer (mCRC) remains controversial. The meta-analyses of subgroup analyses in phase II
Publikováno v:
Biomarkers. 22:178-188
Context: Drug-induced phospholipidosis is one of the significant concerns in drug development, especially in safety assessment and noninvasive diagnostic tool is highly desirable.Objective: The objective of this study is to explored novel biomarkers